OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
Daniel Molnar, Elizabeth M. La, Frederik Verelst, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 4, pp. 827-844
Open Access | Times Cited: 12
Daniel Molnar, Elizabeth M. La, Frederik Verelst, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 4, pp. 827-844
Open Access | Times Cited: 12
Showing 12 citing articles:
Respiratory syncytial virus: challenges in diagnosis and impact on the elderly: Recommendations from a multidisciplinary panel
Lessandra Michelin, Nancy Bellei, Marcelo Ferreira da Costa Gomes, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 5
Lessandra Michelin, Nancy Bellei, Marcelo Ferreira da Costa Gomes, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 5
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
Jonne Terstappen, Sarah F Hak, Anant Bhan, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 12, pp. e747-e761
Closed Access | Times Cited: 5
Jonne Terstappen, Sarah F Hak, Anant Bhan, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 12, pp. e747-e761
Closed Access | Times Cited: 5
Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults
Zhanwei Du, Abhishek Pandey, Seyed M. Moghadas, et al.
Nature Medicine (2025)
Open Access
Zhanwei Du, Abhishek Pandey, Seyed M. Moghadas, et al.
Nature Medicine (2025)
Open Access
The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Older Adults in Italy
Anna Puggina, Filippo Rumi, Eleftherios Zarkadoulas, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 212-212
Open Access
Anna Puggina, Filippo Rumi, Eleftherios Zarkadoulas, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 212-212
Open Access
Economic burden of respiratory syncytial virus in adults in Germany – a health claims analysis between 2015 and 2018
Bennet Huebbe, Anja Mocek, Karina C. Manz, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 1063-1075
Open Access | Times Cited: 2
Bennet Huebbe, Anja Mocek, Karina C. Manz, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 1063-1075
Open Access | Times Cited: 2
Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States
Elizabeth M. La, James E. Graham, David Singer, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Elizabeth M. La, James E. Graham, David Singer, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: a multi-model comparison
Monica Rudd, Alison E. Simmons, Gebremedhin Beedemariam Gebretekle, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Monica Rudd, Alison E. Simmons, Gebremedhin Beedemariam Gebretekle, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Multiple Questions About Protection From Respiratory Syncytial Virus
Stanley A. Plotkin
The Pediatric Infectious Disease Journal (2024) Vol. 43, Iss. 9, pp. 867-868
Closed Access
Stanley A. Plotkin
The Pediatric Infectious Disease Journal (2024) Vol. 43, Iss. 9, pp. 867-868
Closed Access
Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan
Akiko Mizukami, Víctor Preckler, Frederik Verelst, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 986-996
Open Access
Akiko Mizukami, Víctor Preckler, Frederik Verelst, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 986-996
Open Access
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece
George Gourzoulidis, C. Tzanetakos, Argyro Solakidi, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1232-1232
Open Access
George Gourzoulidis, C. Tzanetakos, Argyro Solakidi, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1232-1232
Open Access
Giovanna Elisa Calabrò, Caterina Rizzo, Alexander Domnich, et al.
PubMed (2024) Vol. 65, Iss. 2 Suppl 1, pp. E1-E159
Closed Access
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany
Ahuva Averin, Bennet Huebbe, Mark Atwood, et al.
Expert Review of Vaccines (2024) Vol. 24, Iss. 1, pp. 1-10
Open Access
Ahuva Averin, Bennet Huebbe, Mark Atwood, et al.
Expert Review of Vaccines (2024) Vol. 24, Iss. 1, pp. 1-10
Open Access
